Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on January 24, 2023, covering events occurring on January 23, 2023. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard periodic financial results. Key metrics from the transaction include:
- Total Consideration Raised: $1,299,998.75
- Common Shares Sold: 1,665,384 shares at $0.7806 per share
- Warrants Issued: Warrants to purchase up to 832,692 shares
- Warrant Exercise Price: $0.7181 per share
- Warrant Terms: Exercisable six months after issuance; expires five and one-half years after issuance
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, total debt, or liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the entry into a Material Definitive Agreement (Securities Purchase Agreement) with an accredited investor. This transaction resulted in the issuance of unregistered equity securities under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard representations and warranties typical for this type of transaction. The transaction was executed to raise capital, but the specific use of proceeds is not detailed in the provided text.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the identity of the accredited investor and any potential related-party relationships.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for restrictive covenants.
- Check subsequent filings for the actual use of the approximately $1.3 million raised.
- Monitor the warrant exercise window starting six months post-issuance for potential future dilution.